Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023467 | 1.00 | L3MBTL1 (0.68) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL25009812 | 0.90 | L3MBTL1 (0.76) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL30556174 | 0.90 | L3MBTL1 (0.76) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL29155474 | 0.89 | LMNA (0.72) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL10884343 | 0.88 | LMNA (0.74) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL837646 | 0.86 | LMNA (0.64) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL21243071 | 0.86 | LMNA (0.82) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL25009811 | 0.86 | L3MBTL1 (0.82) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL5363082 | 0.85 | LMNA (0.71) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL9717090 | 0.85 | L3MBTL1 (0.69) | L3MBTL1LMNAKMT2ATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107540605-A | For hair or the choline ester type compound of scalp care | 李明霞 | 2018-01-05 | — | — | CN | claimed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655294-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024157014-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024157019-A1 | PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| CN-115872928-A | Method for preparing pyridine chloride 3-choline formate | 宁波见睿新材料有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-108883099-B | Thiazolidinone compounds and use thereof | 石全 | 2021-09-28 | — | — | CN | disclosed |
| CN-107540605-B | Choline esters for hair or scalp care | 宁波见睿新材料有限公司 | 2020-03-06 | — | — | CN | disclosed |
| EP-2314295-A1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | Resverlogix, Inc (CA) | 2011-04-27 | — | — | EP | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| CN-101365446-A | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery via implantable medical devices | RESVERLOGIX CORP (CA) | 2009-02-11 | — | — | CN | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | disclosed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
| EP-0489581-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1992-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | L3MBTL1 3437/4885LMNA 345/4885KMT2A 2842/4885 |
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | L3MBTL1 215/4885LMNA 1934/4885KMT2A 37/4885 |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | L3MBTL1 3437/4885LMNA 345/4885KMT2A 2842/4885 |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | L3MBTL1 4211/4885LMNA 1518/4885KMT2A 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.